Current Editions
While the pharma emerged unscathed, its deal with the White House has created a precedent for presidents to negotiate drug pricing
Politics, Policy & Law
By including magnesium in its formulation, Tonix is aiming for full oxytocin receptor activation
Product Development
By linking more than 100 cancer trial sites, an Indiana non-profit aims to scale investigator-initiated studies
Product Development
China biotech investor, executive James Li on the rise of China biotech and why it’s only just the beginning
Deals
Emerging Company Profile
With £50M series B round, U.K. start-up set to advance mPTP inhibitors to the clinic for ALS, Parkinson’s
With an in-licensed asset and $205M, San Diego biotech is hoping to fill a gap in second-line gout therapies in the U.S.
Editor's Commentary
Recent statements and actions by the CDER director have confused drug sponsors, demoralized staff
Data Byte
Four new products/indications have positive CHMP opinions or EC approvals
MET-097i’s 14.1% weight loss competitive at 28 weeks; tolerability and dosing frequency could also help it differentiate
Discovery & Translation
BioCentury’s translational roundup also includes enhancers of CAR T cell function and a suite of delivery advances
Politics, Policy & Law
Makary, CDER and CBER leaders expected to meet Monday with BIO, PhRMA
Deals
With Darzalex patent cliff looming, the deal gives the Copenhagen-based biotech a bispecific with blockbuster potential in head and neck cancer
Finance
Eight companies file on HKSE, plus two seek dual listings; NASDAQ’s Ocular, Ovid, Palisade also raise; and VCs back Crystalys, Star, Cartography
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Politics, Policy & Law
Deals
Management Tracks
BioCentury ISSN 1097-7201